Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its brand to MASH treatment.
Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary ...
Zacks Investment Research on MSN
MDGL secures exclusive global right for MASH treatment from PFE
Madrigal Pharmaceuticals MDGL has acquired exclusive global rights to ervogastat from Pfizer PFE, strengthening its pipeline of innovative and combination therapies for metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results